𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo-controlled, double-blind study

✍ Scribed by István Sziklai; Judit Szilvássy; Zoltán Szilvássy

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
124 KB
Volume
121
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives/Hypothesis:

Since the concept of tinnitus dopaminergic pathway emerged, studies have been proposed to investigate if dopaminergic agents influence tinnitus. We hypothesized that pramipexole, an agonist on D2/D3 receptors, may antagonize tinnitus in the presbycusis patients (in the frequency range of 250 to 8,000 Hz) in a dose schedule accepted for the treatment of Parkinson's disease in elderly people.

Study Design:

We designed a randomized, prospective, placebo‐controlled and double‐blind trial.

Methods:

Forty presbycusis patients aged 50 years or older with subjective tinnitus were randomized to two groups (20 patients in both). Patients in the drug group took pramipexole over a period of 4 weeks according to a treatment schedule as follows: week 1, 0.088 mg t.i.d.; week 2, 0.18 mg t.i.d.; week 3, 0.7 mg t.i.d.; week 4, 0.18 mg t.i.d. over 3 days and 0.088 mg t.i.d. the rest of the week. Patients in the second group received placebo. Determination of subjective grading of tinnitus perception, the tinnitus handicap inventory (THI) questionnaire and electrocochleography (ECOG) examinations served as the end points. Subjective audiometry was used to produce secondary data. A significant improvement in tinnitus annoyance is found in the group treated with pramipexole versus placebo with respect to inhibition of tinnitus and a decrease of tinnitus loudness greater than 30 dB. However, neither ECOG nor subjective pure‐tone threshold audiometry revealed any change in hearing threshold in response to either pramipexole or placebo.

Conclusions:

Pramipexole is an effective agent against subjective tinnitus associated with presbycusis at a dose schedule used for the treatment of Parkinson's disease. The drug did not change hearing threshold. Laryngoscope, 2011

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications
✍ Andrew J. Holman; Robin R. Myers 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## Objective To assess the efficacy and safety of pramipexole, a dopamine 3 receptor agonist, in patients with fibromyalgia. ## Methods In this 14‐week, single‐center, double‐blind, placebo‐controlled, parallel‐group, escalating‐dose trial, 60 patients with fibromyalgia were randomiz

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

Dietary intervention in prostate cancer
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study
✍ Ries Kranse; Pieter C. Dagnelie; Monique C. van Kemenade; Frank H. de Jong; Jan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The objective of this study was to show or to exclude an effect of dietary supplement on rising prostate‐specific antigen (PSA) levels. We have studied the effect of a dietary supplement (verum, administered for 6 weeks) containing plant estrogens, antioxidants, including carotenoids, s

Gabapentin in patients with the pruritus
Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial
✍ Nora V. Bergasa; Monnie McGee; Iona H. Ginsburg; Danielle Engler 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the